JP2018527360A5 - - Google Patents

Download PDF

Info

Publication number
JP2018527360A5
JP2018527360A5 JP2018512334A JP2018512334A JP2018527360A5 JP 2018527360 A5 JP2018527360 A5 JP 2018527360A5 JP 2018512334 A JP2018512334 A JP 2018512334A JP 2018512334 A JP2018512334 A JP 2018512334A JP 2018527360 A5 JP2018527360 A5 JP 2018527360A5
Authority
JP
Japan
Prior art keywords
moiety
compound according
protein
compound
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018512334A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018527360A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/052829 external-priority patent/WO2017053391A1/en
Publication of JP2018527360A publication Critical patent/JP2018527360A/ja
Publication of JP2018527360A5 publication Critical patent/JP2018527360A5/ja
Pending legal-status Critical Current

Links

JP2018512334A 2015-09-22 2016-09-21 修飾された細胞毒とその治療的使用 Pending JP2018527360A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562222059P 2015-09-22 2015-09-22
US62/222,059 2015-09-22
PCT/US2016/052829 WO2017053391A1 (en) 2015-09-22 2016-09-21 Modified cytotoxins and their therapeutic use

Publications (2)

Publication Number Publication Date
JP2018527360A JP2018527360A (ja) 2018-09-20
JP2018527360A5 true JP2018527360A5 (https=) 2019-10-31

Family

ID=58276138

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018512334A Pending JP2018527360A (ja) 2015-09-22 2016-09-21 修飾された細胞毒とその治療的使用

Country Status (14)

Country Link
US (3) US10023581B2 (https=)
EP (1) EP3353159A4 (https=)
JP (1) JP2018527360A (https=)
KR (1) KR20180045001A (https=)
CN (1) CN108368075A (https=)
AU (1) AU2016326392B2 (https=)
CA (1) CA2998528A1 (https=)
HK (1) HK1254461A1 (https=)
IL (1) IL257932A (https=)
MX (1) MX380314B (https=)
MY (1) MY193776A (https=)
RU (1) RU2721949C2 (https=)
WO (1) WO2017053391A1 (https=)
ZA (1) ZA201801482B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2998528A1 (en) * 2015-09-22 2017-03-30 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
US10286079B2 (en) 2015-09-22 2019-05-14 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
AU2018237139A1 (en) * 2017-03-22 2019-10-17 The Regents Of The University Of California Modified oligonucleotides and therapeutic uses thereof
WO2021007322A1 (en) * 2019-07-09 2021-01-14 Northwestern University Methods of using modified cytotoxins to treat cancer
IT202100025172A1 (it) 2021-09-30 2023-03-30 Indena Spa Processo per la preparazione di derivati tassanici
KR20250057244A (ko) 2023-10-20 2025-04-29 (주)블루엔씨 고정밀 3d 프린팅 기반 금형 제작 방법 및 장치

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411984A (en) 1992-10-16 1995-05-02 Virginia Tech Intellectual Properties, Inc. Water soluble analogs and prodrugs of taxol
AU6803494A (en) * 1993-06-07 1995-01-03 British Technology Group Limited Anticancer compounds
US5534499A (en) 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
AU735205B2 (en) 1997-05-16 2001-07-05 Commonwealth Scientific And Industrial Research Organisation Vaccine and assay
US5981564A (en) * 1998-07-01 1999-11-09 Universite Laval Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
AU2002953095A0 (en) * 2002-11-29 2002-12-19 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
NO319551B1 (no) 2003-07-04 2005-08-29 Thia Medica As Proteinmateriale fra enkeltceller
GB0321613D0 (en) 2003-09-15 2003-10-15 Drug Discovery Lab As Compounds
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
RU2340616C2 (ru) * 2003-10-29 2008-12-10 Сонус Фармасьютикалз, Инк. Токоферол-модифицированные терапевтические лекарственные соединения
GB0412181D0 (en) * 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
EP1804838A2 (en) * 2004-09-15 2007-07-11 Drug Discovery Laboratory AS Drug conjugates of long chain fatty acid or ester moieties as protein binding prodrugs
JP5755398B2 (ja) 2005-03-18 2015-07-29 ノヴォ ノルディスク アー／エス 伸長されたｇｌｐ−１化合物
TW200731991A (en) * 2005-12-20 2007-09-01 Sonus Pharma Inc Lipophilic di(anticancer drug) compounds, compositions and related methods
KR20100126361A (ko) 2008-02-08 2010-12-01 에일러론 테라퓨틱스 인코포레이티드 치료용 펩티드유사 거대고리
MX2010011165A (es) * 2008-04-10 2011-02-22 Abraxis Bioscience Llc Composiciones de derivados de taxano hidrofobos y sus usos.
WO2010107487A2 (en) 2009-03-18 2010-09-23 Wu Nian Lipid-drug conjugates for drug delivery
EP2413937A1 (en) 2009-04-02 2012-02-08 Shire LLC Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof
WO2011085000A2 (en) 2010-01-06 2011-07-14 The University Of North Carolina At Chapel Hill Fatty acid derivatives and analogs of drugs
CN118767117A (zh) 2010-01-22 2024-10-15 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
JP5980689B2 (ja) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
EP2536434B1 (en) 2010-02-16 2016-04-20 Novo Nordisk A/S Purification method
RU2012151134A (ru) * 2010-05-10 2014-06-20 Дзе Реджентс Оф Дзе Юниверсити Оф Калифорния Логометрическая комбинаторная доставка лекарственных средств
EP2392324A1 (en) * 2010-06-01 2011-12-07 Societe De Coordination De Recherches Therapeutiques Rhenium complexes and their pharmaceutical use
ES2630031T3 (es) 2010-09-28 2017-08-17 Aegerion Pharmaceuticals, Inc. Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada
WO2012050923A2 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action
WO2012048204A2 (en) * 2010-10-08 2012-04-12 Virginia Commonwealth University Prodrugs utilizing a transporter directed uptake mechanism
BR112013033239A2 (pt) 2011-06-22 2016-09-06 Vyome Biosciences pró-farmácos de conjugado baseado em atifungicos e antibacterianos
JP6006309B2 (ja) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
ES2732475T3 (es) 2011-07-08 2019-11-22 Aegerion Pharmaceuticals Inc Polipéptidos modificados por ingeniería genética que tienen una duración potenciada de la acción y una inmunogenicidad reducida
KR101435261B1 (ko) 2012-07-23 2014-09-02 아주대학교산학협력단 항암제-링커-알부민 결합체, 이의 제조방법 및 상기 결합체를 포함하는 약물 전달용 조성물
EP2922817A4 (en) * 2012-11-21 2016-06-22 Univ Sydney OMEGA-3 Analogs
US9962452B2 (en) * 2013-02-04 2018-05-08 Zhuhai Beihai Biotech Co., Ltd. Soluble complexes of drug analogs and albumin
US20160115192A1 (en) * 2013-06-10 2016-04-28 Cedars-Sinai Medical Center Antioxidant, anti-inflammatory and anticancer derivatives of triptolide and nanospheres thereof
CN112043835B (zh) 2013-12-06 2022-10-21 韩捷 用于含氮和羟基的药物的生物可逆引入基团
CN107708702A (zh) * 2014-11-17 2018-02-16 塞勒克塔生物科学有限公司 磷脂醚类似物作为靶向癌症的药物载体
CN104478813A (zh) * 2014-12-20 2015-04-01 苏州博源医疗科技有限公司 5-氟尿嘧啶衍生物、5-氟尿嘧啶免疫原及其抗体与5-氟尿嘧啶检测试剂盒
CA2998528A1 (en) * 2015-09-22 2017-03-30 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
US10286079B2 (en) * 2015-09-22 2019-05-14 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
US20200048198A1 (en) * 2017-03-22 2020-02-13 The Regents Of The University Of California Modified histone deacetylase inhibitors and uses thereof
WO2018175622A1 (en) * 2017-03-22 2018-09-27 The Regents Of The University Of California Modified anthracycline compounds and their therapeutic use
WO2018175601A1 (en) * 2017-03-22 2018-09-27 The Regents Of The University Of California Modified platinum compounds and therapeutic uses thereof
US20200046859A1 (en) * 2017-04-27 2020-02-13 The Regents Of The University Of California Modified mri contrast agents and uses thereof

Similar Documents

Publication Publication Date Title
JP2018527360A5 (https=)
CN104530417B (zh) 一种多官能化h型聚乙二醇衍生物及其制备方法
MX2022003102A (es) Degradadores bifuncionales de brd9 y sus metodos de uso.
JP2016506916A5 (https=)
RU2017112048A (ru) Синергистические комбинации ауристана
JP2017518302A5 (https=)
JP2020097577A5 (https=)
RU2021103727A (ru) Фармацевтические композиции и способы борьбы с кардиотоксичностью, вызванной химиотерапией
JP2016539134A5 (https=)
JP2016532710A (ja) 免疫調節剤としての１，２，４−オキサジアゾール誘導体
EP4410317A3 (en) Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
RU2015149527A (ru) Производные доластатина 10 и ауристатинов
JP2017531619A5 (https=)
CL2014000363A1 (es) Compuestos derivados de 1,2,5-oxadiazoles, inhibidores de indolamina 2,3-dioxigenasa; composicion farmaceutica; proceso para prepararlos; y su uso para el tratamiento de cancer, infeccion viral, depresion, desorden neurodegenerativo, trauma, cataratas, rechazo de transplante de un organo, enfermedades autoinmunes, entre otros.
JP2019521180A5 (https=)
JP2017536344A5 (https=)
JP2008200039A5 (https=)
EP4275748A3 (en) Compositions and methods for treating cns disorders
JP2010509366A5 (https=)
JP2017526677A5 (https=)
JP2017510610A5 (https=)
JP2012506870A5 (https=)
JP2016513696A5 (https=)
CN114206338A (zh) 作为pd-l1抑制剂的二氢化茚类
JP2015512432A5 (https=)